RxDoctor Payments Data

Marcie Beasley

Family · Chattanooga, TNNPI 1679779771

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $61,788 of the $90,679 with a category attached, or 68.1%. 33 manufacturers reported payments, led by Daiichi Sankyo Inc. at 45.8% of the total. Among family clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$90,679in general payments, 2019–2025

Across 198 payments — averaging $457.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$42K
  • Gilead$35K
  • AstraZeneca$11K
  • Seagen Inc.$409
  • Johnson & Johnson$328
  • Regeneron Healthcare Solutions, Inc.$312
  • plus $2K from 27 others

What the payments were for

  • Consulting fees$2,2502%
  • Speaking & faculty fees$61,78868%
  • Travel & lodging$19,85122%
  • Food & beverage$6,6377%
  • Education$1530%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$90,679 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$3,692
Medicare patients
31
Services billed
42

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban18$17,934
EliquisApixaban22$13,607
Exemestane30$9,985
Tamoxifen Citrate132$3,931
Anastrozole120$2,538
Dexamethasone33$616
Ondansetron OdtOndansetron47$608
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen20$527
Hydrocortisone17$465
Letrozole28$464
Hydroxyurea17$298
Oxybutynin Chloride15$266
Pantoprazole Sodium25$237
Potassium Chloride22$228
Lorazepam41$205

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$328$17,93418 claims
PfizerEliquis$59$13,60722 claims
Lilly USA, LLCOlanzapine$22$13117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.

Other family in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →